INDEPENDENT™
MEDICAL ALLIANCE

THE METABOLIC TRAP

Multi-Axis Metabolic Pressure in Cancer Therapy Using Repurposed Drugs and Nutraceuticals

Paul E. Marik, MD, FCCM, FCCP

Updated March 18, 2026

The Metabolic Trap

Cancer cells undergo profound metabolic reprogramming to support rapid proliferation, survival within hostile microenvironments, and resistance to therapy. One of the most well-known examples is the Warburg effect, in which tumor cells rely heavily on aerobic glycolysis rather than mitochondrial oxidative phosphorylation for energy production. This metabolic shift allows cancer cells to generate the biosynthetic precursors required for growth, but it also creates metabolic vulnerabilities that can be targeted therapeutically.

An emerging strategy in oncology is the application of multi-axis metabolic pressure, in which several metabolic pathways are simultaneously disrupted using combinations of repurposed drugs and nutraceuticals. The rationale centers on the metabolic plasticity of cancer cells: when a single metabolic pathway is inhibited, tumors often compensate by switching to alternative fuel sources or signaling pathways.

By targeting multiple axes — such as glucose metabolism, mitochondrial function, mitosis, stress signaling, and circadian/redox regulation — this approach attempts to overwhelm the adaptive capacity of tumor cells and reduce the likelihood of therapeutic resistance.



Repurposed drugs provide a particularly attractive foundation for this strategy because their pharmacology and safety profiles are already well characterized. Agents such as metformin reduce hepatic glucose production and activate AMPK, thereby inhibiting the mTOR pathway and suppressing tumor cell proliferation. Studies suggest that metformin may decrease cancer incidence and mortality in certain populations and can sensitize tumors to other treatments.

Other repurposed agents act on complementary metabolic targets. Antibiotics such as doxycycline impair mitochondrial protein synthesis and may preferentially affect cancer stem cells, while drugs such as ivermectin influence signaling pathways, including PI3K/AKT/mTOR, and can increase oxidative stress and autophagy in tumor cells. Experimental work suggests that combinations such as metformin and ivermectin may produce synergistic antitumor effects by modulating energy metabolism and cell survival pathways.

Nutraceuticals and phytochemicals are frequently incorporated into these multi-target regimens to broaden metabolic pressure while maintaining a favorable toxicity profile. Compounds such as curcumin, EGCG, resveratrol, and sulforaphane influence numerous oncogenic signaling networks, including NF-κB, AMPK, and antioxidant pathways, and may affect cancer stem cell signaling and tumor microenvironmental interactions. Because these agents often act on overlapping but distinct metabolic pathways, combining them with repurposed pharmaceuticals may produce additive or synergistic effects.

Conceptually, multi-axis metabolic therapy can be viewed as a systems-level strategy rather than as a single-drug intervention. By simultaneously targeting energy production, mitochondrial function, cellular stress responses, and tumor-supporting signaling pathways, it aims to create a “metabolic trap” that cancer cells cannot easily escape. The approach aligns with the growing interest in drug repurposing, which seeks to accelerate the development of new cancer therapies by leveraging approved medications with known mechanisms of action and safety profiles.

Figure 1. The Metabolic Trap Framework
Multi-axis metabolic pressure in cancer targeting glucose metabolism, mitochondrial function, mitosis, adrenergic signaling, and circadian/redox regulation using repurposed drugs.



Simultaneous pressure on multiple metabolic systems creates metabolic inflexibility. Cancer cells normally adapt by switching fuels:

- Glucose
- Glutamine
- Fatty acids

However, when multiple metabolic axes are suppressed simultaneously, tumor cells lose the ability to adapt, leading to:

- Energetic collapse
- Impaired proliferation
- Increased susceptibility to apoptosis

The model is a five-axis metabolic trap, with ivermectin as a cross-axis amplifier. The idea is not that each drug kills cancer through a single neat pathway; rather, the combination makes it harder for tumor cells to switch fuels, compartments, or survival programs. That is the core of metabolic inflexibility.

Cancer cells can often escape a single pressure, but they struggle more when glucose signaling, mitochondrial function, mitosis, stress signaling, and circadian/redox adaptation are simultaneously constrained.

The Five Axes

1. Glucose axis: metformin

Metformin primarily lowers the tumor's access to a high-insulin, growth-permissive state and activates AMPK, which suppresses mTOR signaling. In practical terms, this means less anabolic drive, reduced protein and lipid synthesis, and less support for rapid proliferation. This is the "floor-lowering" part of the protocol: it reduces the tumor's baseline metabolic support.

2. Mitochondrial axis: doxycycline

Doxycycline is used here as a mitochondrial stressor. Because mitochondria retain bacterial-like ribosomes, doxycycline can inhibit mitochondrial translation and impair mitochondrial biogenesis and OXPHOS-dependent functions. This is especially relevant to cancer stem-like populations and other cells that rely on mitochondrial fitness for persistence and relapse.

3. Cytoskeleton/mitotic axis: mebendazole

Mebendazole introduces a different kind of stress by interfering with tubulin polymerization and mitotic spindle function. If tumor cells adapt to energy stress by continuing to proliferate, mebendazole places pressure on the machinery required for orderly cell division. It has also demonstrated anti-angiogenic and other pleiotropic anticancer effects in preclinical studies.

4. Stress-signaling axis: propranolol

Propranolol targets the adrenergic side of tumor biology. Beta-adrenergic signaling can promote invasion, angiogenesis, metastatic behavior, and an immunosuppressive microenvironment. Blocking that pathway may reduce one of the tumor's major external survival signals, particularly under physiologic stress.

5. Circadian/redox axis: melatonin

Melatonin differs from the other agents because it acts more as a regulator than a blunt inhibitor. In cancer literature, it has been linked to circadian regulation, redox modulation, apoptosis signaling, immune effects, and, in some contexts, treatment sensitization. In this framework, melatonin is used to make it harder for tumor cells to exploit oxidative stress adaptation and circadian dysregulation as survival mechanisms.

Where Ivermectin Fits

Ivermectin is best understood as a bridge drug rather than a sixth isolated axis. Preclinical reports link it to Wnt/β-catenin inhibition, YAP-, PAK-, and AKT–mTOR-related effects, importin-mediated trafficking effects, and mitochondrial and oxidative stress.

This means ivermectin can reinforce several parts of the trap at once: stemness signaling, survival signaling, and mitochondrial vulnerability. In other words, it helps connect the glucose axis to the mitochondrial and stress-response axes.

Why the Combination Is Coordinated Rather Than Random

Tumors often escape treatment by rerouting metabolic pathways. If glucose pressure increases, tumor cells may rely more heavily on mitochondria or fatty acids. If mitochondrial pressure increases, they may increase glycolysis or shift toward a more proliferative phenotype. If external stress hormones support invasion and survival, tumor cells may remain viable despite metabolic pressure. If circadian and redox regulation are disrupted, tumor cells may tolerate hostile conditions more effectively.

A coordinated combination attempts to block several of these escape routes at once, leaving cancer cells with fewer compensatory options. That is the biochemical logic of the trap.

Figure 2. The Metabolic Trap Model
Conceptual model of how coordinated targeting of glucose metabolism, mitochondrial function, mitosis, adrenergic signaling, and circadian/redox pathways may induce metabolic inflexibility in cancer cells.





THANKS TO YOU, THIS ‘THE METABOLIC TRAP’ GUIDE IS FREE!

We’re 100% donor-supported. Your gift enables us to do this critical research and create these life-saving, FREE resources.

IMA is a 501(c)(3) organization. Your gift is tax-deductible.

Help make resources like this possible.

Donate Today!

IMAhealth.org/donate

INDEPENDENT™ MEDICAL ALLIANCE